The current market size for the pharma CRAM (contract research and manufacturing) business in India has been estimated to be $1.2 B, with an expectation that this will increase to more than $5 B in the next 5 years. Indian CRAM providers like Dr. Reddy, Nicholas Piramal, and Dishman have expressed that they are well positioned for this upsurge as India has good infrastructure and quality --- and lower cost structures which are attractive to pharma MNCs.
Outsourcing Pharma reports that Indian generic drug maker Aurobindo Pharma will also enter this segment with its new CRAM businesss. AuroSource. The new division will provide API development in 6 facilities across India and sport an R&D facility in Pashamylaram near the Hyderabad pharma/biotech hub.
Posted by Bruce Lehr March 8th 2010
Comments